Literature DB >> 11929837

Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy.

Dennis E J G J Dolmans1, Ananth Kadambi, John S Hill, Christina A Waters, Byron C Robinson, Jeffrey P Walker, Dai Fukumura, Rakesh K Jain.   

Abstract

The antivascular effects of photodynamic therapy (PDT) and their mechanisms are not clearly understood. Here, we examined the effects of PDT with a novel photosensitizer MV6401 on the microvasculature in a mammary tumor (MCaIV) grown in a murine dorsal skinfold chamber and in normal tissue controls. The mice were irradiated with light 15 min after i.v. administration of MV6401 when the drug was localized only in the vascular compartment, as shown by fluorescence microscopy and immunohistochemistry. PDT with MV6401 caused a dose-dependent biphasic blood flow stasis and vascular hyperpermeability, as determined by intravital microscopy. This biphasic response was classified into two components: (a) an acute response observed immediately after PDT; and (b) a long-term response observed at times greater than 3 h after PDT. The acute temporal vascular effects were characteristic of vasoconstriction but not of thrombus formation. However, the long-term vascular shutdown was mediated by thrombus formation, as evidenced by histological evaluation and inhibition with heparin. Minimal effects were observed in normal vessels after antivascular doses used against the tumor, but there was no long-term vascular damage. In concert with the stasis, a dose-dependent tumor growth delay was observed. This study provides mechanistic insights into antitumor vascular effects of PDT and suggests novel strategies for tumor treatment with PDT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929837

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Tumor vascular microenvironment determines responsiveness to photodynamic therapy.

Authors:  Amanda L Maas; Shirron L Carter; E Paul Wileyto; Joann Miller; Min Yuan; Guoqiang Yu; Amy C Durham; Theresa M Busch
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

3.  Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.

Authors:  A Chiaviello; I Paciello; I Postiglione; E Crescenzi; G Palumbo
Journal:  Cell Prolif       Date:  2010-10       Impact factor: 6.831

Review 4.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

5.  Antitumor activity of photodynamic therapy with a chlorin derivative in vitro and in vivo.

Authors:  Lai-Xing Wang; Jian-Wei Li; Jian-Yue Huang; Jian-Hong Li; Li-Jun Zhang; Donal O'Shea; Zhi-Long Chen
Journal:  Tumour Biol       Date:  2015-04-07

Review 6.  Diverse Applications of Nanomedicine.

Authors:  Beatriz Pelaz; Christoph Alexiou; Ramon A Alvarez-Puebla; Frauke Alves; Anne M Andrews; Sumaira Ashraf; Lajos P Balogh; Laura Ballerini; Alessandra Bestetti; Cornelia Brendel; Susanna Bosi; Monica Carril; Warren C W Chan; Chunying Chen; Xiaodong Chen; Xiaoyuan Chen; Zhen Cheng; Daxiang Cui; Jianzhong Du; Christian Dullin; Alberto Escudero; Neus Feliu; Mingyuan Gao; Michael George; Yury Gogotsi; Arnold Grünweller; Zhongwei Gu; Naomi J Halas; Norbert Hampp; Roland K Hartmann; Mark C Hersam; Patrick Hunziker; Ji Jian; Xingyu Jiang; Philipp Jungebluth; Pranav Kadhiresan; Kazunori Kataoka; Ali Khademhosseini; Jindřich Kopeček; Nicholas A Kotov; Harald F Krug; Dong Soo Lee; Claus-Michael Lehr; Kam W Leong; Xing-Jie Liang; Mei Ling Lim; Luis M Liz-Marzán; Xiaowei Ma; Paolo Macchiarini; Huan Meng; Helmuth Möhwald; Paul Mulvaney; Andre E Nel; Shuming Nie; Peter Nordlander; Teruo Okano; Jose Oliveira; Tai Hyun Park; Reginald M Penner; Maurizio Prato; Victor Puntes; Vincent M Rotello; Amila Samarakoon; Raymond E Schaak; Youqing Shen; Sebastian Sjöqvist; Andre G Skirtach; Mahmoud G Soliman; Molly M Stevens; Hsing-Wen Sung; Ben Zhong Tang; Rainer Tietze; Buddhisha N Udugama; J Scott VanEpps; Tanja Weil; Paul S Weiss; Itamar Willner; Yuzhou Wu; Lily Yang; Zhao Yue; Qian Zhang; Qiang Zhang; Xian-En Zhang; Yuliang Zhao; Xin Zhou; Wolfgang J Parak
Journal:  ACS Nano       Date:  2017-03-14       Impact factor: 15.881

7.  Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes.

Authors:  Dandan Luo; Jumin Geng; Nasi Li; Kevin A Carter; Shuai Shao; G Ekin Atilla-Gokcumen; Jonathan F Lovell
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

8.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

9.  Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.

Authors:  Denise Bechet; Loraine Tirand; Béatrice Faivre; François Plénat; Corinne Bonnet; Thierry Bastogne; Céline Frochot; François Guillemin; Muriel Barberi-Heyob
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

10.  Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.

Authors:  Noa Madar-Balakirski; Catherine Tempel-Brami; Vyacheslav Kalchenko; Ori Brenner; David Varon; Avigdor Scherz; Yoram Salomon
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.